Beyang Therapeutics Raises Nearly $30 Million for AI Drug Platform

August 12, 2026
Beyang Therapeutics closed an oversubscribed Series A round of nearly $30 million to advance its ExCEED drug design platform and clinical pipeline.

Chengdu based Beyang Therapeutics has closed an oversubscribed Series A round raising nearly $30 million, the company said in a press release. The round was co led by Legend Capital and Shanghai Healthcare Capital, with participation from China Medical System Holdings, Fenglei Capital, Shanghai Sci-Tech Innovation Center Capital, Harbor & Canton Capital, Root Venture Partners, and YuanBio Venture Capital.

Beyang said the funding will support updates to its ExCEED platform, which combines proprietary databases, AI, and computational simulation for molecular design, druggability optimization, and biological evaluation. The company also plans to use the proceeds for clinical and preclinical work on pipeline candidates and to expand international research and business teams.

The company said its BT01001 candidate is a small molecule eye drop for retinal diseases that has completed Phase I SAD and MAD studies in healthy subjects. Beyang is preparing patient trials for the therapy.

Beyang is also advancing BT01002, a second generation Menin inhibitor for KMT2Ar or NPM1 mutated acute leukemia. The candidate is in IND enabling studies.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

AI Funding News Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Funding

08/12
Bullen Ultrasonics Gets Ohio Grant for AI Manufacturing Optimization
08/12
Blacksmith Raises $45 Million for Code Validation Cloud
08/12
EnableComp Acquires Helix Advisory for Revenue Recovery Technology
08/12
Cognition in Talks for Funding at $40 Billion Valuation
08/12
Accel Closes $550 Million India Fund for AI and Other Startups

More from: Life Sciences

08/12
RyboDyn Maps Hidden Human Proteome With AI Platform
08/12
EnableComp Acquires Helix Advisory for Revenue Recovery Technology
08/12
PointClickCare Launches Vox Advantage for Senior Care Documentation
08/12
Ubie Smart Support Qualifies on Mayo Clinic Platform
08/12
Ninenovo Publishes Wearable Ring Study on Bilateral Cardiovascular Monitoring

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like